KFDA to settle down safety issue on Celebrex.
Published: 2006-02-08 06:58:00
Updated: 2006-02-08 06:58:00
The KFDA decided to change labelling of all non-steroid anti-inflammatory drugs (NSAIDs) including celebrex, aceclofenac, meloxicam, ibuprofen and naproxen. Thus, the safety problem of Pfizer's Celebrex has been sorted out.
Managing director Cho Seong-ja said on Feb. 2 "we respect the KFDA's ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
